Heron Therapeutics (NASDAQ:HRTX) Upgraded by StockNews.com to Buy Rating

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating in a note issued to investors on Tuesday.

Separately, Needham & Company LLC reiterated a "buy" rating and set a $4.00 price target on shares of Heron Therapeutics in a research report on Wednesday, December 4th.

Heron Therapeutics Trading Up 1.5 %

NASDAQ HRTX traded up $0.03 on Tuesday, hitting $1.66. The company's stock had a trading volume of 963,263 shares, compared to its average volume of 1,414,493. The firm has a market cap of $251.73 million, a P/E ratio of -9.19 and a beta of 1.60. Heron Therapeutics has a 52-week low of $1.04 and a 52-week high of $3.93. The company's 50-day simple moving average is $1.47 and its 200 day simple moving average is $1.93.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) EPS for the quarter, hitting analysts' consensus estimates of ($0.03). The business had revenue of $32.81 million during the quarter, compared to analysts' expectations of $36.40 million. During the same period in the previous year, the business earned ($0.17) EPS. On average, research analysts forecast that Heron Therapeutics will post -0.13 EPS for the current fiscal year.

Institutional Trading of Heron Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Congress Park Capital LLC boosted its stake in Heron Therapeutics by 24.1% during the fourth quarter. Congress Park Capital LLC now owns 2,455,495 shares of the biotechnology company's stock worth $3,757,000 after acquiring an additional 477,417 shares in the last quarter. Clearline Capital LP lifted its holdings in shares of Heron Therapeutics by 48.9% during the third quarter. Clearline Capital LP now owns 2,226,512 shares of the biotechnology company's stock valued at $4,431,000 after purchasing an additional 731,246 shares during the last quarter. Marshall Wace LLP boosted its position in shares of Heron Therapeutics by 256.2% in the 2nd quarter. Marshall Wace LLP now owns 1,761,051 shares of the biotechnology company's stock worth $6,164,000 after purchasing an additional 1,266,697 shares in the last quarter. AQR Capital Management LLC grew its stake in shares of Heron Therapeutics by 1,460.9% in the 2nd quarter. AQR Capital Management LLC now owns 607,135 shares of the biotechnology company's stock worth $2,125,000 after buying an additional 568,238 shares during the last quarter. Finally, GSA Capital Partners LLP increased its position in Heron Therapeutics by 18.4% during the 3rd quarter. GSA Capital Partners LLP now owns 512,736 shares of the biotechnology company's stock valued at $1,020,000 after buying an additional 79,680 shares in the last quarter. 80.01% of the stock is owned by hedge funds and other institutional investors.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.